This company listing is no longer active
TRACON Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
TRACON Pharmaceuticals has a total shareholder equity of $-3.1M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $7.4M and $10.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$6.27m |
| Equity | -US$3.09m |
| Total liabilities | US$10.49m |
| Total assets | US$7.40m |
Recent financial health updates
Recent updates
Tracon Pharmaceuticals announces $35M non-dilutive debt facility
Sep 06Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma
Aug 29Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M
Aug 10TRACON Pharmaceuticals announces $5M registered direct offering
Dec 29TRACON Pharma launches $8.8M direct offering
Dec 22Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study
Dec 10Tracon Pharma files China application for envafolimab in solid tumors
Nov 16Financial Position Analysis
Short Term Liabilities: TCON has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: TCON has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: TCON is debt free.
Reducing Debt: TCON's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: TCON has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: TCON has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/04 21:14 |
| End of Day Share Price | 2024/12/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TRACON Pharmaceuticals, Inc. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Cross | Alliance Global Partners |
| Joel Beatty | Baird |
| null null | BTIG |